Drugs / BAFFR-CAR T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07369492 | Jan 2026 → Jan 2027 expected | lymphoma | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05370430 | Jun 2022 → Jul 2027 expected | B-cell non-Hodgkin lymphoma | PeproMene Bio, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04690595 | May 2021 → Nov 2026 expected | B-cell acute lymphoblastic leukemia | PeproMene Bio, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | PeproMene Bio, Inc. | Results PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure pepromenebio.com ↗
The publication reports durable complete clinical responses, together with a more favorable safety profile compared with approved CAR T-cell therapies. |
| 2025-11-20 | PeproMene Bio, Inc. | Results PeproMene Bio’s PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting pepromenebio.com ↗
Interim results from the Phase 1 dose-escalation studies (NCT04690595, NCT05370430) support BAFF-R as a differentiated target designed to overcome CD19 antigen escape while maintaining durable activity and low toxicity. |
| 2025-05-20 | PeproMene Bio, Inc. | Results PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response pepromenebio.com ↗
We are excited to report that a patient with r/r FL has achieved complete remission after treatment with PMB-CT01, bringing the total to seven patients-all achieving a 100% CR rate with durable responses and a manageable safety profile. |
| 2024-08-07 | PeproMene Bio, Inc. | Results PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells pepromenebio.com ↗
The study reported robust indicators of polyfunctionality, which correlated with successful CAR T cell expansion post-infusion and the patient’s ongoing remission. |
| 2024-01-23 | PeproMene Bio, Inc. | Results PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in the Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope pepromenebio.com ↗
PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) clinical trial of PMB-CT01 (BAFFR-CAR T Cells) has reached complete remission at one-month post treatment. |
| 2023-09-13 | PeproMene Bio, Inc. | Results PeproMene Bio, Inc. Announced Completion of the First Dose Cohort and Opening of the Second Dose Cohort in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) pepromenebio.com ↗
The Overall Response Rate is 100% (two Complete Response and one Partial Response) at one-month post treatment. |
| 2022-12-20 | PeproMene Bio, Inc. | Results PeproMene Bio, Inc. Announced Complete Response of The First Patient Treated in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope pepromenebio.com ↗
We are pleased to see a deep complete remission which is minimal residual disease negative, |
| 2017-12-11 | PeproMene Bio, Inc. | Results Dr. Hong Qin posted a paper at ASH meeting pepromenebio.com ↗
Method and Results: We adapted a scFv based on our humanized anti-BAFF-R antibody onto a second generation CAR platform containing CD3ζ and 4-1BB intracellular signaling domains. |
All press releases naming this drug 9 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAFFR-CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04690595 ↗ |
| Known as | BAFF-R CAR T-cell | “Finally, we applied our assay to the autologous BAFF-R CAR T-cell product generated from the first patient with non-Hodgkin lymphoma treated in an ongoing clinical trial who...” PMID 38885481 ↗ Aug 2024 |
| Action | Deplete | “These BAFFR-specific T cells may help the body's immune system identify and kill BAFFR+ cancer cells.” NCT04690595 ↗ |
| Modality | Cell therapy | “B-cell activating factor receptor-Chimeric antigen receptor T cells” NCT04690595 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT07369492 ↗ |